Paul Galardy, MD
ALL Specialist
19 years treating Acute Lymphocytic Leukemia
-min_405a5b96-bc32-43d1-a9b3-8c080e7ff9c8.jpg?alt=media&token=d6549ea4-2f87-412d-8f87-9cb210d99ec6)
Clinical Expertise
- Leukemia, Acute Lymphoblastic (ALL)
- Bone Marrow Transplant
About
Paul J. Galardy, M.D., studies the role of the ubiquitin-proteasome system in the pathogenesis of cancer.
Ubiquitin (Ub), a small highly conserved protein, is attached to proteins in order to change their function or localization, or direct them to the proteasome for degradation. The specificity of Ub attachment is regulated by two large enzyme families called ubiquitin ligases and de-ubiquitinating enzymes (DUBs), with ligases responsible for attachment and DUBs catalyzing the removal of Ub. Many critical cellular events are under the control of this system, including those of cell division. It is therefore not surprising that a growing list of human cancers is associated with deregulated activity of these enzymes. Dr. Galardy's specific focus is on the involvement of DUBs in the development of cancer.
Location
Mayo Clinic Rochester: Gonda Building, 200 1st St SW, Rochester, MN 55905, USA
Get the latest thought leadership on Acute Lymphocytic Leukemia delivered straight to your inbox.
Subscribe to the weekly "HealthTree Community for Acute Lymphocytic Leukemia Newsletter" for Acute Lymphocytic Leukemia news, life with Acute Lymphocytic Leukemia stories, Acute Lymphocytic Leukemia clinical trials, Acute Lymphocytic Leukemia 101 articles and events with Acute Lymphocytic Leukemia experts.
HealthTree Foundation is a qualified 501(c)(3) tax-exempt organization.
Copyright © 2023 HealthTree Foundation. All rights reserved.
Tax ID 45-5354811